Jazz Pharmaceuticals plc
JAZZ
$229.63
$0.440.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -10.77% | 6.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.77% | 6.38% | |||
| Cost of Revenue | -14.46% | -12.38% | |||
| Gross Profit | -10.39% | 8.80% | |||
| SG&A Expenses | -15.71% | 10.37% | |||
| Depreciation & Amortization | 1.51% | 0.82% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.43% | -0.09% | |||
| Operating Income | -22.47% | 28.88% | |||
| Income Before Tax | 43.56% | 2,218.80% | |||
| Income Tax Expenses | 22.91% | 102.05% | |||
| Earnings from Continuing Operations | 44.06% | -19.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.06% | -19.08% | |||
| EBIT | -22.47% | 28.88% | |||
| EBITDA | -14.03% | 17.12% | |||
| EPS Basic | 42.11% | -19.56% | |||
| Normalized Basic EPS | 19.46% | 36.15% | |||
| EPS Diluted | 38.13% | -21.39% | |||
| Normalized Diluted EPS | 16.22% | 33.02% | |||
| Average Basic Shares Outstanding | 1.38% | 0.60% | |||
| Average Diluted Shares Outstanding | 4.20% | 2.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||